{
    "clinical_study": {
        "@rank": "75606", 
        "arm_group": {
            "arm_group_label": "Individualized Anemia Mangement Protocol", 
            "arm_group_type": "Experimental", 
            "description": "Single arm study, therefore all patients will participate in the following:\nPhase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.\nPhase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
        }, 
        "brief_summary": {
            "textblock": "Hypothesis: Routine clinical tests with feedback control based Epogen(Epo)/Venofer(Iron)\n      protocol will improve Hemoglobin (Hgb) stability and increase the time that patients remain\n      in target\n\n      Objectives:\n\n        1. Decreased variability of Hgb\n\n        2. Increase the % of patients in target range c Increase in time that Hgb remains target\n           range"
        }, 
        "brief_title": "The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability", 
        "condition": [
            "Anemia", 
            "End Stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Design One dialysis unit shift comprising up to 200 patients. Study participation will\n      last for 12 months broken into 3 phases as described below.\n\n      Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols\n      (AMP) while patients are receiving standard medical care.\n\n      Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period:\n      return to standard-care AMP.\n\n      The individual AMP will be utilized weekly during the 9 months of Phase 2.\n\n      The 3 objectives will be evaluated and updated weekly, Baseline to Year 1.\n\n      All Epo dosing recommendations must be reviewed by the treating physician who can either\n      accept or modify doses at his/her discretion based on clinical event that are not includes\n      in the transmitted data such as bleeding, infection, and hospitalization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years old or older\n\n          -  Receiving hemodialysis in an out-patient dialysis unit\n\n        Exclusion Criteria:\n\n          -  Not receiving EPOGEN as part of their standard medical care\n\n          -  Patient refusal"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975844", 
            "org_study_id": "BH-12-197"
        }, 
        "intervention": {
            "arm_group_label": "Individualized Anemia Mangement Protocol", 
            "description": "Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.\nPhase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP .", 
            "intervention_name": "Individualized Anemia Mangement Protocol", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anemia", 
            "End Stage Renal Disease"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicopee", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01013"
                }, 
                "name": "Chicopee Dialysis Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability", 
        "overall_official": {
            "affiliation": "Baystate Medical Center", 
            "last_name": "Michael J Germain, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in average intraindividual Hgb variability between control period and treatment periods.", 
            "measure": "Intraindividual Hemoglobin (Hgb) variability", 
            "safety_issue": "Yes", 
            "time_frame": "Evaluated and updated weekly for 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975844"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Baystate Medical Center", 
            "investigator_full_name": "Michael Germain", 
            "investigator_title": "Medical Director, Renal Transplantation, Department of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in average Hgb levels between control treatment periods, and change in interindividual Hgb variability between control treatment periods.", 
            "measure": "Average hemoglobin levels", 
            "safety_issue": "Yes", 
            "time_frame": "Evaluated and updated weekly for 52 weeks"
        }, 
        "source": "Baystate Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Western New England Renal & Transplant Associates, PC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Michael Germain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Study has been terminated due to lack of financial support"
    }
}